Vaxzevria is named as an intervention in 3 current clinical trials in our Canada, South Korea and Australia registers. 1 is recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Canadian Immunization Research Network (1). The most-studied condition is COVID-19. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
NCT06550882 · ClinicalTrials.gov ↗ · Acquired Hemophilia A
|
Observational | Recruiting | Takeda | South Korea |
|
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
NCT04894435 · ClinicalTrials.gov ↗ · COVID-19
|
Phase 2 | Active, closed | Canadian Immunization Research Network | Canada |
|
Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
NCT05110911 · ClinicalTrials.gov ↗ · Influenza, Human, SARS-CoV-2 Infection
|
Observational | Active, closed | University of Melbourne | Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Vaxzevria. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Pragmatic Randomized Trial to Evaluate the Relative Effectiveness of Abrysvo® Revaccination Versus a Single Primary Dose for Preventing RSV-associated Lower Respiratory Tract Disease in Immunocompromised Adults (DAN-RSV IC REVAX)
2026-527536-14-00 · Virus Diseases
|
Phase 4 | Authorised | Region Hovedstaden, Pfizer Inc | Denmark |
|
Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial
RSVaxID
2025-524374-42-00 · Surgical Procedures, Operative
|
Phase 2 | Authorised | Hospices Civils De Lyon | France |
| Lead sponsor | Trials |
|---|---|
| Canadian Immunization Research Network | 1 |
| Takeda | 1 |
| University of Melbourne | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in South Korea | 1 | 1 |
| Clinical trials in Australia | 1 | 0 |
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
3 current trials in our Canada, South Korea and Australia registers name Vaxzevria (also registered as ChAdOx1-S) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Canadian Immunization Research Network (1), Takeda (1) and University of Melbourne (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Vaxzevria works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vaxzevria works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vaxzevria (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.